Wockhardt Q1 FY27 Results Analysis: EBITDA Margin Expands 1091 bps, PAT Swings to Profit (WOCKPHARMA)

Cofacto Research Updated August 10, 2026 2 min read

Wockhardt Ltd reported Q1 FY27 numbers. Here's a quick read of what worked, what to watch, and what management said.

Quick Details

Results date	August 10, 2026
Quarter	Q1 FY 2026-2027
Revenue (Q1)	Rs. 929.00 Cr (+25.88% YoY)
PAT (Q1)	Rs. 107.00 Cr
EBITDA margin	20.67% (+1091 bps YoY)
EPS (Q1)	Rs. 6.55
Market cap	Rs. 32,326.17 Cr
CMP	Rs. 1,989.40

Quarter Snapshot

Wockhardt reported a strong operational turnaround with consolidated revenue up 25.88% YoY and EBITDA margin expanding 1091 bps to 20.67%. The company achieved a clean PAT of Rs.107 Cr versus a loss last year, aided by the completed US generics exit and strong domestic growth. Key catalysts include the Zaynich FDA approval and credit rating upgrade, though near-term margins may be impacted by launch costs.

Key Investment Insights

Key Positives

Consolidated revenue grew 25.88% YoY to Rs.929 Cr.
Consolidated EBITDA margin expanded from 9.76% to 20.67% YoY.
PAT swung from a loss of Rs.108 Cr to a profit of Rs.107 Cr.
Standalone revenue surged 35.84% YoY to Rs.561 Cr.
ICRA upgraded long-term rating to A- (Stable) from BBB (Positive).
U.S. FDA approval for Zaynich (cUTI) received.
Subsidiaries turned from a Rs.159 Cr PAT drag to a negligible Rs.1 Cr drag.

Risk Factors

Consolidated EBITDA margin contracted QoQ from 23.32% to 20.67%, partly due to normal seasonality and Zaynich pre-launch cost build.
Standalone EBITDA margin declined slightly YoY from 31.72% to 28.16%.
Other income contributed 29% of PAT (Rs.31 Cr out of Rs.107 Cr), indicating reliance on non-operating income.
Inventory build of Rs.22 Cr boosted P&L, a timing effect under Ind AS 2.